Following the observation detected in a previous study that X chromosome monosomy in Turner’s syndrome genotypes was associated with a sporadic loss and/or gain of other chromosomes, we studied here whether this instability is a consistent finding in constitutional autosomal trisomies. We used PHA-stimulated lymphocytes derived from 14 patients (10 patients with trisomy 21, 2 with trisomy 18, and 2 with trisomy 13). Fourteen healthy controls were compared. Fluorescence in situ hybridization, applied at interphase cells, was used to evaluate the level of aneuploidy for 3 randomly selected chromosomes (autosomes 8, 15, and 16) in each sample. For each tested chromosome, our results showed a significantly higher level of aneuploid cells in the samples from the patients than in those from controls, with no difference between the patient groups. The mean level of aneuploid cells (percentage) for all 3 tested autosomes was almost twice as high in the patient samples as in the control samples. The aneuploidy level was mainly due to monosomy, which was significantly higher in the samples from the patients than in those from controls for each one of the tested chromosomes, with no difference between the patient groups. The mean level of monosomic cells (percentage) for all 3 tested chromosomes was almost twice as high in the patient samples as in the control samples. Our study shows that various constitutional autosomal trisomies are associated with an increased frequency of non-chromosome specific aneuploidy and is a continuation of the previous study documenting sporadic aneuploidy in Turner’s sample cells. It is possible that primary aneuploid cells destabilize their own genome resulting in variable aneuploidy of other chromosomes. It is also possible that one or several common factor(s) is/are involved in both constitutional and sporadic aneuploidy.

Keywords:
Autosome, Constitutional trisomies, FISH, Sporadic aneuploidy
1.
Amiel A, Avivi L, Gaber E, Fejgin MD: Asynchronous replication of allelic loci in Down syndrome. Eur J Hum Genet 6:359–364 (1998).
2.
Amiel A, Korenstein A, Gaber E, Avivi L: Asynchronous replication of alleles in genomes carrying an extra autosome. Eur J Hum Genet 7:223–230 (1999).
3.
Antonarakis SE, Lyle R, Dermitzakis ET, Rymond A, Deutsch S: Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat Rev Genet 5:725–738 (2004).
4.
Baker DJ, van Deursen JM: Chromosome missegregation causes colon cancer by APC loss of heterozygosity. Cell Cycle 9:1711–1716 (2010).
5.
Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, et al: BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 36:744–749 (2004).
6.
Baker DJ, Chen J, van Deursen JM: The mitotic checkpoint in cancer and aging: what have mice taught us? Curr Opin Cell Biol 17:583–589 (2005).
7.
Bean CJ, Hunt PA, Millie EA, Hassold TJ: Analysis of malsegregating mouse Y chromosome: evidence that the earliest cleavage divisions of the mammalian embryo are non-disjunction prone. Hum Mol Genet 10:963–972 (2001).
8.
Dobie KW, Hari KL, Maggert KA, Karpen GH: Centromere proteins and chromosome inheritance: a complex affair. Curr Opin Genet Develop 9:206–217 (1999).
9.
Duesberg P, Li R: Multistep carcinogenesis – a chain reaction of aneuploidization. Cell Cycle 2:202–210 (2003).
10.
Duesberg P, Rasnick D: Aneuploidy, the somatic mutation that makes cancer a species of its own.Cell Motil Cytoskeleton 47:81–107 (2000).
11.
Ford JH: Spindle microtubular dysfunction in mothers of Down syndrome children. Hum Genet 68:295–298 (1984).
12.
Ganmore I, Smooha G, Izraeli S: Constitutional aneuploidy and cancer predisposition. Hum Mol Genet 18:R84–R93 (2009).
13.
Hassold T, Hunt P: To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet 2:280–291 (2001).
14.
Jacobs PA: The role of chromosome abnormalities in reproductive failure. Reprod Nutr Dev Suppl 1:63S–74S (1990).
15.
Jacobs PA, Hassold TJ: The origin of numerical chromosome abnormalities. Adv Genet 33:101–133 (1995).
16.
Pidoux AL, Allshire RC: Centromeres: getting a grip of chromosome. Curr Opin Cell Biol 12:308–319 (2000).
17.
Rasnick D: Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. Cancer Genet Cytogenet 136:66–72 (2002).
18.
Reish O, Gal R, Gaber E, Sher C, Bistrizer Z, Amiel A: Asynchronous replication of biallelically expressed loci: a new phenomenon in Turner syndrome. Genet Med 4:439–443 (2002).
19.
Reish O, Brosh N, Gobazov R, Rosenblat M, Libman V, Mashevich M: Sporadic aneuploidy in PHA-stimulated lymphocytes of Turner’s syndrome patients. Chromosome Res 14:527–534 (2006).
20.
Shi Q, King RW: Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 13:1038–1042 (2005).
21.
Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW: Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11:25–36 (2007).
22.
Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, et al: Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322:703–709 (2008).
23.
Yeshaya J, Amir I, Rimon A, Freedman J, Shohat M, Avivi L: Microdeletion syndromes disclose replication timing alterations of genes unrelated to the missing DNA. Mol Cytogenet 2:11 (2009).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.